Navigation Links
Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
Date:10/27/2008

MISSISSAUGA, ON, Oct. 27 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced that study results showing that Pennsaid, Nuvo's topical diclofenac solution, is an effective treatment option for the symptoms of osteoarthritis of the knee, with an improved safety profile compared to oral diclofenac, were detailed in a poster presentation at the 2008 American College of Rheumatology Scientific Meeting in San Francisco.

The lead author of the presentation was Dr. Lee Simon, Associate Clinical Professor of Medicine, Harvard Medical School. This was the first presentation to a medical and scientific audience of the Phase III clinical study results, which were originally announced by the Company upon study completion in January 2006.

"Presenting at a prestigious event such as the American College of Rheumatology Scientific Meeting provides Nuvo with a forum to share our compelling Pennsaid clinical data with medical and scientific leaders," said Dr. Brad Galer, Vice President and General Manager of Nuvo's Pain Group. "As we move closer to Pennsaid's approval by the U.S. FDA, it is important that the professional rheumatology community be aware of what we believe is the strongest clinical efficacy and safety evidence of any topical NSAID formulation for the treatment of osteoarthritis. We believe that this data supports the conclusion that Pennsaid, once approved, will be the best-in-class product available in the U.S."

"These results confirm and extend previous studies and show that this novel topical diclofenac solution is efficacious for the relief of symptoms in patients with symptomatic knee osteoarthritis," said Dr. Marc C. Hochberg, Head, Division of Rheumatology & Clinical Immunology at the University of Maryland School of Medicine. "F
'/>"/>

SOURCE Nuvo Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alzheimers Association Grant Furthers Successful Research at UMass Lowell
2. Local Research Foundation Achieves Milestone in Fight Against Cancer
3. Congresswoman Supporting Spinal Cord Research Intended to Benefit U.S. Veterans
4. American College of Cardiology and Center of Excellence for Simulation Research of Western Michigan University (CESR) Partner for in situ Simulation to Improve Team Communication and Door-to-Balloon (D2B) Time
5. Susan G. Komen for the Cure(R) Makes Unprecedented Research and Local Program Grants
6. Michael J. Fox Foundation Awards $2 Million for Research on Cognitive and Mood Symptoms of Parkinsons Disease
7. Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing
8. Wild Blueberries Take Top Spot in New Antioxidant Research Study
9. Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees
10. Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Depomed, Inc. (Nasdaq: ... offer, subject to market and other conditions, $230 million ... (the "Notes"). Depomed, Inc. ("Depomed") expects to grant the ... up to an additional $34.5 million aggregate principal amount ... RBC Capital Markets, LLC will act as joint book-running ...
(Date:9/2/2014)... signs monitoring devices market with over 40% market share, ... American and European vital signs monitors markets is expected ... the end of 2013. They have been driving the ... people across these economies. The European market is expected ... rising demand for home health patient monitoring devices due ...
(Date:9/2/2014)... YORK , Sept. 2, 2014 ... is available in its catalogue: Acute ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... 2014 Summary GlobalData,s clinical trial ... H2, 2014" provides data on the Acute Heart ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
... at 59th American Academy of Neurology Annual Meeting, ... /PRNewswire/ --,PTC Therapeutics, Inc. (PTC), a biopharmaceutical company ... targeting,post-transcriptional control processes, today announced positive,interim data from ... patients,with Duchenne muscular dystrophy (DMD) due to a ...
Cached Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 5
(Date:9/3/2014)... September 03, 2014 An inspiring story ... be documented in the season finale of “Extreme Weight ... and his teenage daughter from Highlands Ranch, Colo. who ... she weighs 265 pounds. Their challenge is to team ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:9/3/2014)... Gorda, FL (PRWEB) September 03, 2014 ... healthcare delivery, increases patient safety, decreases medical errors, ... providers. , To mark the important role ... in America, IHS and others across the U.S. ... Technology (NHIT) Week , September 16-20, 2014. With ...
(Date:9/3/2014)... 2014 Independent review is a ... evidence-based health care along the continuum. Health plans, ... expertise of accredited independent review organizations (IROs) at ... , As a core function, IROs provide objective, ... of medical necessity. Yet backed by expertise, they ...
(Date:9/2/2014)... IA (PRWEB) September 03, 2014 IMCA ... will kick off on September 1, 2014 at the ... 6, the pre-race ceremony will include a check presentation ... For The Warriors® is a national nonprofit organization that ... the fallen who have sustained physical and psychological wounds ...
(Date:9/2/2014)... concentrated pot might be risky business for women, ... The study is the first to demonstrate sex ... , Psychology professor Rebecca Craft showed that, ... at least 30 percent more sensitive than males ... ingredient in cannabis. Females also develop tolerance to ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3
... is a statement by ADA President John S. ... (D-Mich.) and Candice Miller (R-Mich.) for introducing the ... that would bolster America,s capacity to respond to ... of the extensive education, training and professionalism of ...
... can divide into two, first it must duplicate its genetic ... of chromosomes then have to be separated from one another ... both daughter cells are genetically identical to the original, or ... called the centrosome, and a copy of the centrosome, position ...
... ONTARIO, CANADA Canada may not be able to ... brain drain of the mid-90s as a result of ... CMAJ published online today http://www.cmaj.ca/cgi/rapidpdf/cmaj.090209 . Health ... the public and government understand the impact of the ...
... (NYSE: RMD ) today announced record revenue and ... the December 2008 quarter was $223.0 million, a 10% increase ... quarter ended December 31, 2007. For the quarter ended ... net income was $33.9 million, an increase of 18% and ...
... study says , , THURSDAY, Feb. 5 (HealthDay News) -- Nearly ... that could lead to paralysis or death, but greater use ... a new study finds. , "Wearing a seat belt is ... against potentially devastating injury," said lead researcher Dr. Marjorie C. ...
... Feb. 5 A coalition of concerned consumer advocate ... Medical Consumers, called on the New York State Legislature ... pharmaceutical company gifts to doctors. This ban would exclude ... focus on gifts valued at over fifty dollars. Pharmaceutical ...
Cached Medicine News:Health News:Statement by ADA President John S. Findley on the Dental Emergency Responder Act Introduced Today by Reps. Stupak and Miller 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 7Health News:Spine Injuries a Common Result of Car Crashes 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 3
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: